Christina Cheddar Berk

Nvidia is a fan of Recursion Pharmaceuticals. Data expected from the company will help determine valuations for stocks using AI to discover new drugs.

Sticky inflation has produced savvy consumers, who are very deliberate about where they spend their money. That’s an advantage for some retailers.

Novo Nordisk saw price pressure for its GLP-1 drugs Ozempic and Wegovy. Investors want to know how Eli Lilly's Zepbound performed.

"Investors were nervous going in and this print would come as a huge relief," said Mohit Bansal, an analyst at Wells Fargo.

Month after month of soaring prices has wreaked havoc on household finances.These retailers with saavy store brands stand to benefit.

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Frenzied shopping on Black Friday will prove make-or-break for stores, and dividing lines will distinguish between the winners and losers in the retail sector.

The initial euphoria over the GLP-1 drugs like Ozempic has mellowed, but catalysts expected in 2025 could energize investor interest in the stocks.

"We believe renewed consumer attention on the role of processed foods in the public health crisis is just getting started," said TD Cowen's Robert Moskow.

CEO Greg Ebel sees the series of proposed tariffs as a negotiating tactic.